M. Angelescu *, Cristina Beldescu **, Ioana Anca ***
* Prof. dr. Mircea Angelescu, Institutul de Boli Infecțioase “Prof. dr. Matei Balș”, București
** Dr. Cristina Beldescu, medic specialist M.G., Pasteur Merieux • Conmaught Rhone-Poulenc Group, București
*** Dr. Ioana Anca, medic primar pediatru, șef de lucrări, Clinica de pediatrie, Spit. “Prof. A. Rusescu”, UMF “Carol Davila”, București
Abstract
The viral diseases of the respiratory tract are considered, among the transmisible diseases the most frecquent cause of morbidity. Within this category, Influenza derives its “major” importance from the rapidity with which epidemics evolve, the widespread morbidity, and seriousness of complication, notably viral and bacterial pneumonia. The Influenza epidemics evolution could be influenced by immunisation status of the population; as much as peoples is vaccinated against Influenza the epidemics is expected to have a limited evolution. Due to frecquent mutations of the genes encoding the surface glycoproteins of the influenza virus, World Health Organisation Centres for Reference and Research on Influenza make yearly recommendations for vaccine components to be used by the vaccine producers next year. According to the experience of Infectious Disease Institute “Prof. Dr. Matei Bal “ – Bucure ti with VAXIGRIPR (a Pasteur Merieaux Connaught product), this is easy to use, has no side effects, is offering a quite good protection and its cost is accessible according with its quality.